A&B gets probiotic patent for treatment of chronic digestive diseases

28 Nov 2017

A&B Ingredients has announced that its probiotic PA5051 has been issued a new patent as a method for treatment of chronic digestive diseases including inflammatory bowel disorder and nonspecific enteropathy.

A&B gets probiotic patent for treatment of chronic digestive diseases

A&B Ingredients has announced that its probiotic PA5051 has been issued a new patent as a method for treatment of chronic digestive diseases. The new patent covers both inflammatory bowel disorder (IBD) and nonspecific enteropathy (NEP), and can be used as a treatment for both humans and animals.

The newly issued patent adds to PA5051’s portfolio of patents and expands the novel applications of PA5051 on reducing the side effects of prescription medicines such as steroids and immune suppressors The probiotic PA5051 was recently issued patents for: decreasing both the dosages and application times of steroid and immune suppressor agents for autoimmune diseases, inflammatory bowel disease, inflammatory-like bowel disease, immune mediated hemolytic anemia, or atopic dermatitis.

“PA5051 is a unique natural, plant-based non-spore forming probiotic that is proven to aid in chronic digestive disorders among humans and animals,” said Gil Bakal, A&B Ingredients’ Managing Director. “Derived from wild grasses, PA5051 works extremely well with antibiotics, steroids and immune suppressors functioning as an immune modulator to lower inflammation.”

Bakal noted that because PA5051 is plant-based, it is also a vegan-friendly probiotic.